Protein Chromatography Impurity Clearance Patents
28.7% of all 651 records sit with just five assignees, yet the ranked field runs 100 companies deep — concentration at the top, a long tail below it. Filings hit their peak in 2017 at 39 records. From 2021 (7) to 2024 (5) — the last year treatable as complete — activity fell 29%. Years after 2024 are still filling in under the publication lag and should not be read as a continued decline.
- 1AGENCY FOR SCI TECH & RES67
- 2BIO RAD LABORATORIES INC35
- 3EMD MILLIPORE CORP32
- 4COHERUS ONCOLOGY INC27
- 5GENZYME CORP26
See the full protein chromatography impurity clearance analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most patents in protein chromatography impurity clearance?
The ranked list covers 100 companies, with one clear leader holding 67 records — more than double the fifth-place count of 26. The top five assignees combined account for 28.7% of all 651 records in scope, and the top ten for 44.9%. Below the leading group the ranking thins into a long tail of companies with only a handful of filings each, so a full freedom-to-operate check needs to look well past the leader alone.
Is patent filing activity in this field growing or shrinking?
Filing peaked in 2017 at 39 records and has cooled since; the 2021-to-2024 window, the most recent stretch that can be treated as complete, shows a 29% decline from 7 to 5 filings. Counts for 2025 and 2026 are still low, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop in activity. The honest read is a slowdown through 2024, with the true 2025-26 picture not yet visible.
Which patent classes cover protein chromatography impurity clearance?
C07K (peptides and proteins) is the dominant class, appearing in 90.8% of the 651 records in scope, followed by C12N (microorganisms and genetic engineering) at 45.0%. Separation-process claims under B01D appear in 28.7% of records, and catalysis-related B01J claims in only 13.1%. Because a single record can carry several IPC classes, these shares add up to more than 100% and should not be summed into a single total.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Protein Chromatography Impurity Clearance covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.